These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36674584)

  • 1. No Placebo Effect beyond Regression to the Mean on the Six Minute Walk Test in Pulmonary Arterial Hypertension Trials.
    Anheyer D; Bugaj TJ; Lüdtke R; Appelbaum S; Trübel H; Ostermann T
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
    Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis.
    Vizza CD; Badagliacca R; Messick CR; Rao Y; Nelsen AC; Benza RL
    Int J Cardiol; 2018 Mar; 254():299-301. PubMed ID: 29254882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
    McCarthy BE; McClelland RL; Appleby DH; Moutchia JS; Minhas JK; Min J; Mazurek JA; Smith KA; Fritz JS; Pugliese SC; Urbanowicz RJ; Holmes JH; Palevsky HI; Kawut SM; Al-Naamani N
    Chest; 2022 Aug; 162(2):436-447. PubMed ID: 35247393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension.
    Heresi GA; Rao Y
    Lung; 2020 Dec; 198(6):933-938. PubMed ID: 33211166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.
    Gaine S; Simonneau G
    Eur Respir Rev; 2013 Dec; 22(130):487-94. PubMed ID: 24293464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
    Ventetuolo CE; Moutchia J; Baird GL; Appleby DH; McClelland RL; Minhas J; Min J; Holmes JH; Urbanowicz RJ; Al-Naamani N; Kawut SM
    Ann Am Thorac Soc; 2023 Jan; 20(1):58-66. PubMed ID: 36053665
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 11. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
    Stollfuss B; Richter M; Drömann D; Klose H; Schwaiblmair M; Gruenig E; Ewert R; Kirchner MC; Kleinjung F; Irrgang V; Mueller C
    J Med Internet Res; 2021 Oct; 23(10):e25163. PubMed ID: 34623313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.
    Gupta R; Baughman RP; Nathan SD; Wells AU; Kouranos V; Alhamad EH; Culver DA; Barney J; Carmona EM; Cordova FC; Huitema M; Scholand MB; Wijsenbeek M; Ganesh S; Birring SS; Price LC; Wort SJ; Shlobin OA
    Respir Med; 2022 May; 196():106801. PubMed ID: 35316723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J; Gao Y; Deng B; Liu K
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
    Pan HM; McClelland RL; Moutchia J; Appleby DH; Fritz JS; Holmes JH; Minhas J; Palevsky HI; Urbanowicz RJ; Kawut SM; Al-Naamani N
    Eur Respir J; 2023 Jul; 62(1):. PubMed ID: 37169384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension.
    Saxer S; Lichtblau M; Berlier C; Hasler ED; Schwarz EI; Ulrich S
    Lung; 2019 Oct; 197(5):617-625. PubMed ID: 31263960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
    Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
    J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.
    Khanna D; Zhao C; Saggar R; Mathai SC; Chung L; Coghlan JG; Shah M; Hartney J; McLaughlin V
    Arthritis Rheumatol; 2021 May; 73(5):837-847. PubMed ID: 33538058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.
    Souza R; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Le Brun FO; Mehta S; Perchenet L; Pulido T; Sastry BKS; Sitbon O; Torbicki A; Rubin LJ; Simonneau G
    PLoS One; 2018; 13(3):e0193226. PubMed ID: 29590122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.